Dementia with Lewy bodies and Parkinson’s disease dementia-twoindependent disorders or one clinical entity within a clinical spectrum ofsynucleinopathies?
DOI:
https://doi.org/10.2478/cpp-2020-0015Keywords:
dementia with Lewy bodies, Lewy body disease, dementia, synucleinopathiesAbstract
Introduction. Both dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are important dementia syndromes that overlap in their clinical features and clinical course, neuropathological abnormalities, and also therapeutic approach. Nevertheless it is still unclear whether DLB and PDD are two different disorders that require differentiation or are one clinical entity within a spectrum of Lewy body disease. Currently these disorders are mainly distinguished on the basis of the relative timing of the onset of symptoms of dementia and parkinsonism. The present paper presents current concepts on the pathogenesis of both disorders and their possible overlap.
Material and methods. Online databases in the field of DLB and PDD were searched for to find potentially eligible articles. Only most recent articles published after the year 2000 were chosen.
Results. The clinical features of DLB and PDD are similar and include dementia with hallucinations and cognitive fluctuations, as well as parkinsonian signs. Also cognitive deficits are similar in PDD and in DLB, with predominance of executive dysfunction, visual-spatial deficits and memory impairment. Neuropathological changes in both disorders involve the presence of Lewy bodies and Lewy neurites within brainstem, limbic and neocortex, as well as loss of midbrain dopamine cells, and loss of cholinergic neurons in the nuclei of ventral forebrain.
Conclusions. Similarities in clinical manifestation, neuropsychological deficits and neuropathological abnormalities may suggest that both DLB and PDD are two different phenotypes of the same disorder. This review article presents current knowledge on similarities and differences between these two clinical entities and raises the question whether they require differentiation or not.
References
1. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88-100.
2. Aarsland D, Ballard CG, Halliday G. Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol.2004;17:137-45.
3. Aarsland D, Londos E, Ballard C. Parkinson’s disease dementia and dementia with Lewy bodies: different aspects of one entity. IntPsychogeriatr.2009;21:216-19.
4. Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. 2016; 22:435-63.
5. Barker RA, Williams-Gray CH. Review: the spectrum of clinical features seen with alpha synuclein pathology. NeuropatholApplNeurobiol. 2016;42:6-19.
6. Jellinger KA. Significance of brain lesions in Parkinson dis-ease dementia and Lewy body dementia. Front NeurolNeurosci. 2009;24:114-125.
7. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson’s disease. ParkinsonismRelatDisord. 2004;10:15-18.
8. Friedman JH. Dementia with Lewy Bodies and Parkinson Disease Dementia: It is the same Disease. Parkinsonism RelatDisord2018 46Suppl1:6-9.
9. Lewy FH. Paralysis agitans. I. PathologischeAnatomie. Lewandowsky’s Handbuch der Neurologie, 3 Band: SpezNeurologieII.Berlin, Springer, Germany: 1912:920-33.
10. Lippa CF, Duda JE, Grossman M,Hurtig HI, Aarsland D, Boeve BF, et al.DLB/PDD Working Group. DLB and PDD boundary issues: diagnosis, treatment,molecular pathology, and biomarkers. Neurology. 2007;68:812-819.
11. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863- 72.
12. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. MovDisord. 2007;22:1689–07.
13. Fearnley JM, Lees AJ. Ageing and Parkinson’sdisease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
14. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, et al.Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-411.
15. Mattila PM, Roytta ̈M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease. ActaNeuropathol. 1998;95:576-82.
16. Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J NeurolSci. 2016;43(Suppl 1):83-95.
17. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. MovDisord 2005;20:1255-63.
18. Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007;254:38-45.
19. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 25:1596-602.
20. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. MovDisord. 2008;23:837-44.
21. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J NeurolSci. 2010;289:18-22.
22. Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson’ s disease dementia the same disease? BMC Med. 2018;16:34.
23. Wong YC, Krainc D. Alpha-synuclein toxicity in neurodegeneration: mechanism and terapeutic strategies. Nat Med. 2017;23:1-13.
24. Ince PG. Dementia with Lewy bodies and Parkinson's disease dementia. In: Dickson DW, Weller RO, Dickson DW, ROs W, editors. Neurodegeneration: the molecular pathology of dementia and movement disorders, 2nd edition. Oxford: Blackwell Publishing Ltd; 2011:224-237.
25. Bellani S, Sousa VL, Ronzitti G, Valtorta F, Meldolesi J, Chieregatti E. The regulation of synaptic function by alpha-synuclein. CommunIntegr Biol. 2010;3:106-109.
26. Brooks DJ, Piccini P. Imaging in Parkinson’s disease: the role of monoamines in behavior. Biol Psychiatry 2006;59:908-918.
27. Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, et al. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129:729-748.
28. Jellinger KA. Neuropathology of Parkinson’s disease. In: Thomas M, Thomas M, editors. Inflammation in Parkinson’s disease: scientific and clinical aspects. Springer; 2014; New York: 25-47.
29. Kalaitzakis ME, Pearce RK, Gentleman SM. Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies. NeurosciLett. 2009;461:12-15.
30. Park KW, Kim HS, Cheon SM, Cha JK, Kim SH, Kim JW. Dementia with Lewy bodies versus Alzheimer’s disease and Parkinson’s disease dementia: a comparison of cognitive profiles. J Clin Neurol. 2011;7:19-24.
31. Takemoto M, Sato K, Hatanaka N, Yamashita T, Ohta Y, Hishikawa N, et al. Different clinical and neuroimaging characteristics in early stage Parkinson’s disease with dementia and dementia with Lewy bodies. J Alzheimers Dis. 2016;52:205-211.
32. Blanc F, Mahmoudi R, Jonveaux T, Galmiche J, Chopard G, Cre-tin B, et al. Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse. Alzheimers Res Ther. 2017;9:47.
33. Kramberger MG, Auestad B, Garcia-Ptacek S, Abdelnour C, Olmo JG, Walker Z, et al. Long-term cog-nitive decline in dementia with Lewy bodies in a large mul-ticenter, international cohort. J Alzheimers Dis. 2017;57:787-795.
34. Walker Z, McKeith I, Rodda J, Qassem T, Tatsch K, Booij J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer’s disease: a cohort study. BMJ Open.2012;2:e000380.
35. Goetz CG, Emre M, Dubois B. Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol.2008;64Suppl2:81-92.
36. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain.2002;125:391-403.
37. Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, Perez J, Ribosa-Nogue R, Marin J, et al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. MovDisord. 2016;31:45-52.
38. DelliPizzi S, Franciotti R, Taylor JP, Thomas A, Tartaro A, Onofrj M, et al. Thalamic involvement in fluctuating cognition in dementia with Lewy bodies: magnetic resonance evidences. CerebCortex. 2015;25:3682-3689.
39. Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77:875-882.
40. Kim WS, Kagedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014;6:73.
41. Thomas AJ, Attems J, Colloby SJ, O’Brien JT, McKeith I, Walker R, et al.Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology.2017;88:276-283.
42. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. MovDisord. 2015;30:1591-1601.
43. Fritz NE, Kegelmeyer DA, Kloos AD, Linder S, Park A, Kataki M, et al. Motor performance differentiates individuals with Lewy body dementia, Parkinson’s and Alzheimer’s disease. Gait Posture. 2016;50:1-7.
44. Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkin-son’s disease and parkinsonian dementias. J Clin Psychiatry.2005;66:633-7.
45. Donaghy PC, O’Brien JT, Thomas AJ.Prodromal dementia with Lewy bodies. Psychol Med. 2015:45:259-268.
46. Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J NeurolNeurosurg Psychiatry. 2015;86:135-143.
